VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PTGX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PTGXProtagonist Therapeutics, Inc.
$121.88$7.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPTGXQuarterly Financials

Protagonist Therapeutics, Inc. (PTGX) Quarterly Financials

120+ quarters historyFree accessUpdated daily

Protagonist Therapeutics, Inc. (PTGX) quarterly income statement — complete revenue, gross profit & net income history

PTGX Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23
Sales/Revenue07.44M4.71M5.55M28.32M170.64M4.67M4.17M254.95M60M00
Revenue Growth %-100%-95.64%0.79%33.09%-88.89%184.4%------100%
Cost of Goods Sold000000000000
COGS % of Revenue------------
Gross Profit07.44M4.71M5.55M28.32M170.64M4.67M4.17M254.95M60M00
Gross Margin %-100%100%100%100%100%100%100%100%100%--
Gross Profit Growth %-100%-95.64%0.79%33.09%-88.89%184.4%------100%
Operating Expenses60.02M57.79M51.13M47.59M47.63M43.86M46.13M42.96M48.64M36.95M38.33M42.35M
OpEx % of Revenue-777.09%1085.17%858.04%168.18%25.7%986.7%1030.96%19.08%61.59%--
Selling, General & Admin13.28M11.43M11.13M10.55M11.74M8.95M10.16M9.44M14.91M8.05M7.66M9.17M
SG&A % of Revenue-153.74%236.21%190.25%41.45%5.25%217.28%226.54%5.85%13.42%--
Research & Development46.74M46.36M40M37.04M35.89M34.9M35.97M33.52M33.73M28.9M30.66M33.18M
R&D % of Revenue-623.34%848.96%667.8%126.74%20.46%769.41%804.42%13.23%48.16%--
Other Operating Expenses000000000000
Operating Income-3.65M-50.35M-46.42M-42.04M-19.31M126.78M-41.45M-38.79M206.31M23.05M-38.33M-42.35M
Operating Margin %--677.09%-985.17%-758.04%-68.18%74.3%-886.7%-930.96%80.92%38.41%--
Operating Income Growth %81.11%-139.72%-11.98%-8.37%-109.36%450.05%-8.16%8.41%672.75%163.12%-18.65%-2.2%
EBITDA-3.65M-49.98M-46.06M-41.74M-19.07M127.32M-40.81M-37.32M206.54M23.88M-37.5M-41.53M
EBITDA Margin %--672.03%-977.5%-752.56%-67.34%74.61%-872.86%-895.54%81.01%39.8%--
EBITDA Growth %80.87%-139.26%-12.88%-11.84%-109.23%433.13%-8.82%10.15%686.96%166.94%-19.23%-2.3%
D&A (Non-Cash Add-back)0376K361K304K239K536K647K1.48M236K832K827K821K
EBIT0-50.35M-39.34M-42.04M-19.31M126.78M-41.45M-38.79M206.31M23.05M-38.33M-42.35M
Net Interest Income06.76M7.05M7.41M7.57M6.85M7.68M7.4M4.38M4.24M4.25M3.91M
Interest Income5.88M6.76M7.05M7.41M7.57M6.85M7.68M7.4M4.38M4.24M4.25M3.91M
Interest Expense000000000000
Other Income/Expense5.93M6.64M7.08M7.44M7.66M6.88M7.82M7.5M4.36M4.29M4.22M3.89M
Pretax Income2.28M-43.72M-39.34M-34.6M-11.65M133.66M-33.63M-31.29M210.67M27.34M-34.1M-38.46M
Pretax Margin %--587.84%-834.87%-623.86%-41.15%78.33%-719.36%-750.95%82.63%45.56%--
Income Tax-1.5M666K0172K01.99M-420K-676K3.33M000
Effective Tax Rate %-65.85%-1.52%0%-0.5%0%1.49%1.25%2.16%1.58%0%0%0%
Net Income3.78M-44.38M-39.34M-34.77M-11.65M131.67M-33.21M-30.62M207.34M27.34M-34.1M-38.46M
Net Margin %--596.8%-834.87%-626.96%-41.15%77.17%-710.37%-734.73%81.32%45.56%--
Net Income Growth %132.46%-133.71%-18.46%-13.57%-105.62%381.7%2.62%20.4%714.8%179.94%-9.2%6.28%
Net Income (Continuing)3.78M-44.38M-39.34M-34.77M-11.65M131.67M-33.21M-30.62M207.34M27.34M-34.1M-38.46M
Discontinued Operations000000000000
Minority Interest000000000000
EPS (Diluted)0.05-0.69-0.62-0.55-0.191.98-0.54-0.503.260.44-0.58-0.68
EPS Growth %126.32%-134.85%-14.81%-10%-105.83%350%6.9%26.47%625.81%168.75%4.92%18.07%
EPS (Basic)0.06-0.69-0.62-0.55-0.192.11-0.54-0.503.410.45-0.58-0.68
Diluted Shares Outstanding70.49M63.57M63.77M63.51M62.96M66.41M61.77M61.31M63.6M61.8M59.18M56.78M
Basic Shares Outstanding65.09M63.57M63.77M63.51M62.96M62.33M61.77M61.31M60.86M60.39M59.18M56.78M
Dividend Payout Ratio------------